July 23, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Share:
ASKA Pharmaceutical, Takeda Pharmaceutical and Others Sign Licensing Agreement for Tavocept
 

Tokyo, Mar 21, 2006 (JCN) - ASKA Pharmaceutical and Takeda Pharmaceutical have signed a licensing agreement with BioNumerik Pharmaceuticals and KI Pharmaceuticals, a joint venture company of ASKA and BioNumerik, for Tavocept, a chemoprotective agent developed by BioNumerik.

Under the agreement, Takeda will be able to sell Tavocept exclusively in Japan, making upfront payments to ASKA, BioNumerik and KI, as well as milestone payments and royalties. Furthermore, ASKA will continue its current clinical trials of the agent in Japan at the expense of Takeda. KI will retain co-promotion rights in Japan.

Tavocept prevents and mitigates the incidence, severity and duration of peripheral nerve damage associated with chemotherapy drugs.

By Aki Tsukioka Contributor

Copyright © 2014 JCN. All rights reserved. A division of Japan Corporate News Network KK.



ACN Newswire
 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)